Coronary artery stenting and eptifibatide treatment in diabetes


Journal Article

We evaluated data from the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial regarding the outcomes of diabetic patients using eptifibatide, a small molecule glycoprotein IIb/IIIa inhibitor. Eptifibatide treatment during nonurgent coronary stent implantation was associated with a similar relative reduction in adverse ischemic complications in both diabetic and nondiabetic patients.

Duke Authors

Cited Authors

  • McLellan, CS; O'Shea, JC; Tcheng, JE; Labinaz, M

Published Date

  • April 1, 2004

Published In

Volume / Issue

  • 21 / 4

International Standard Serial Number (ISSN)

  • 1092-6607

Citation Source

  • Scopus